Cargando…

A systematic review of dosing frequency with bone-targeted agents for patients with bone metastases from breast cancer

BACKGROUND: Bone-targeted agents are usually administered to breast cancer patients with bone metastases every 3–4 weeks. Less frequent (‘de-escalated’) treatment may provide similar benefits with improved safety and reduced cost. METHODS: To systematically review randomised trials comparing de-esca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hutton, Brian, Addison, Christina L., Campbell, Kaitryn, Fergusson, Dean, Mazarello, Sasha, Clemons, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2013
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723383/ https://www.ncbi.nlm.nih.gov/pubmed/26909282 http://dx.doi.org/10.1016/j.jbo.2013.05.001

Ejemplares similares

Bone-Targeted Agents for the Management of Breast Cancer Patients with Bone Metastases
por: Simos, Demetrios, et al.
Publicado: (2013)

Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey
por: Hutton, Brian, et al.
Publicado: (2013)

De-escalated administration of bone-targeted agents in patients with breast and prostate cancer—A survey of Canadian oncologists
por: Hutton, Brian, et al.
Publicado: (2013)

A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases
por: Addison, Christina L, et al.
Publicado: (2014)

Incidence, consequences and treatment of bone metastases in breast cancer patients—Experience from a single cancer centre
por: Kuchuk, I., et al.
Publicado: (2013)

Oral care and the use of bone-targeted agents in patients with metastatic cancers: A practical guide for dental surgeons and oncologists
por: Kuchuk, Iryna, et al.
Publicado: (2013)

Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
por: Tu, Megan M., et al.
Publicado: (2021)

Incidence and consequences of bone metastases in lung cancer patients
por: Kuchuk, Michael, et al.
Publicado: (2013)

Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey
por: Alzahrani, Mashari, et al.
Publicado: (2021)

Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey
por: AlZahrani, Mashari, et al.
Publicado: (2020)

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial)
por: Hilton, John, et al.
Publicado: (2018)

Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer
por: Clemons, Mark, et al.
Publicado: (2021)

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer
por: Hilton, J.F., et al.
Publicado: (2017)

Strategies for obtaining bone biopsy specimens from breast cancer patients – Past experience and future directions
por: Ibrahim, Mohammed F.K., et al.
Publicado: (2016)

Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer
por: D’Oronzo, Stella, et al.
Publicado: (2020)

Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting
por: Zhu, Xiaofu, et al.
Publicado: (2014)

A primer of bone metastases management in breast cancer patients
por: Petrut, B., et al.
Publicado: (2008)

Role of bone-anabolic agents in the treatment of breast cancer bone metastases
por: Suvannasankha, Attaya, et al.
Publicado: (2014)

Doxycycline-Induced Changes in Circulating MMP or TIMP2 Levels Are Not Associated with Skeletal-Related Event-Free or Overall Survival in Patients with Bone Metastases from Breast Cancer
por: Zhao, Huijun, et al.
Publicado: (2023)

Does estrogen play a role in response to adjuvant bone-targeted therapies?
por: Russell, Kent, et al.
Publicado: (2013)

Detection of PIK3CA Mutations in Breast Cancer Bone Metastases
por: Daneshmand, Manijeh, et al.
Publicado: (2012)

Effects of de-escalated bisphosphonate therapy on the Functional Assessment of Cancer Therapy-Bone Pain, Brief Pain Inventory and bone biomarkers
por: Kuchuk, Iryna, et al.
Publicado: (2013)

Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS)
por: Fernandes, Ricardo, et al.
Publicado: (2016)

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review
por: Fernandes, Ricardo, et al.
Publicado: (2017)

Clinical Practice Guidelines and Consensus Statements in Oncology – An Assessment of Their Methodological Quality
por: Jacobs, Carmel, et al.
Publicado: (2014)

Feasibility outcomes of a randomised, multicentre, pilot trial comparing standard 6-monthly dosing of adjuvant zoledronate with a single one-time dose in patients with early stage breast cancer
por: Awan, Arif, et al.
Publicado: (2020)

Therapeutic targets for bone metastases in breast cancer
por: Clézardin, Philippe
Publicado: (2011)

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study
por: Addison, Christina L., et al.
Publicado: (2015)

Radiation therapy combined with bone-modifying agents ameliorates local control of osteolytic bone metastases in breast cancer
por: Tanaka, Hidekazu, et al.
Publicado: (2020)

The Impact of Lung Carcinoma Histology on the Frequency of Bone Metastases
por: Oliveira, Marcelo Bragança dos Reis, et al.
Publicado: (2019)

Combination of Bone-Modifying Agents with Immunotarget Therapy for Hepatocellular Carcinoma with Bone Metastases
por: Chen, Zhaoyu, et al.
Publicado: (2022)

Bone metastases in breast cancer: Frequency, metastatic pattern and non-systemic locoregional therapy
por: Steinauer, Kirsten, et al.
Publicado: (2014)

A national portfolio of bone oncology trials—The Canadian experience in 2012
por: Kuchuk, I., et al.
Publicado: (2012)

Prevalence of bone metastases and bone-targeting agent use among solid tumor patients in the United States
por: Hernandez, Rohini K, et al.
Publicado: (2015)

Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in real-world practice in six European countries
por: von Moos, Roger, et al.
Publicado: (2017)

Patient perceptions and expectations regarding imaging for metastatic disease in early stage breast cancer
por: Simos, Demetrios, et al.
Publicado: (2014)

Comparison of physical interventions, behavioral interventions, natural health products, and pharmacologics to manage hot flashes in patients with breast or prostate cancer: protocol for a systematic review incorporating network meta-analyses
por: Hutton, Brian, et al.
Publicado: (2015)

Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States
por: Qian, Yi, et al.
Publicado: (2017)

Prevention of bone metastases and management of bone health in early breast cancer
por: Gnant, Michael, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_e9t32ve61b5e11efgaqi83ksvm